After induction chemotherapy, before the start of radiochemotherapy the most common grade 1–2 adverse event observed was anemia in 79.6% of patients, followed by an increase in CRP grade 1–2 in 55.3% of patients and increased LDH grade 1–2 in 43.6% of patients. Here, CRP is linked to anemia (phenotype).